Is pemetinib/pemetinib included in the national medical insurance?

Pemigatinib (Pemigatinib) is an oral small molecule drug that has gradually entered the public eye in recent years. It is mainly targeted at patients with specific types of tumors, such as cholangiocarcinoma (CCA). With the in-depth development of precision medicine, targeted therapy drugs are constantly updated and iterated. In addition to the efficacy, what many patients are most concerned about is their price and medical insurance coverage. According to the current domestic open market situation, pemetinib has been approved for marketing in China, but has not yet entered the national medical insurance directory. This means that patients still need to bear their own costs for clinical application, which has a greater financial burden than traditional chemotherapy drugs or some targeted drugs that have been included in medical insurance.

In terms of market supply, domestic pharmaceutical companies and import channels have provided two main specifications, namely 4.5 mg 14 tablets and 9 mg 14 tablets in packaging formats, making it easier for doctors to choose according to different medication plans of patients. Although there is currently no medical insurance support, pemetinib still attracts clinical attention due to its clear targeting mechanism and application prospects. From a policy perspective, adjustments to the national medical insurance catalog are often closely related to the clinical value of drugs, market demand and negotiation results. With the accumulation of relevant real-world research data and the increase in international guideline recommendations, we do not rule out the opportunity to be included in the medical insurance directory in the future, thus significantly reducing the financial pressure on patients.

For patients, whether to enter medical insurance is not only an economic relief, but also directly related to the accessibility of treatment. Cancer patients often require long-term medication. If the medication can be reimbursed by medical insurance, compliance will be significantly improved. Overseas experience also shows that the value of pemetinib in precise classification treatment is gradually recognized, which to a certain extent also lays the foundation for its entry into medical insurance. Therefore, whether pemetinib can be included in medical insurance in the next few years deserves continued attention.

Reference materials:https://go.drugbank.com/drugs/DB15102